a Paediatric Intensive Care Unit, Woman-Mother-Child Department, University Hospital Lausanne, Switzerland
b Clinic of Neonatology, Woman-Mother-Child Department, University Hospital Lausanne, Switzerland
c Paediatric Cardiology, Woman-Mother-Child Department, University Hospital Lausanne, Switzerland
d Children’s Research Centre, University Children’s Hospital, University of Zurich, Switzerland
e Newborn Research, Department of Neonatology, University and University Hospital of Zurich, Switzerland
f Child Development Centre, University Children’s Hospital, University of Zurich, Switzerland
g Division of Development and Growth, Department of Paediatrics, University Hospitals and Faculty of Medicine, University of Geneva, Switzerland
h Paediatric Cardiology, Woman-Child-Adolescent Department, University Hospitals and Faculty of Medicine, University of Geneva, Switzerland
i Paediatric Neurology, Bern, Switzerland
j Paediatric Cardiology, Centre for Congenital Heart Disease, Department of Cardiology and Cardiac Surgery, University Children’s Hospital, University of Bern, Switzerland
k Department of Paediatric Intensive Care and Neonatology, University Children’s Hospital, University of Zurich, Switzerland
l Paediatric and Neonatal Intensive Care Unit, Department of Paediatrics, Gynecology and Obstetrics, University Hospitals and Faculty of Medicine, University of Geneva, Switzerland.
m Paediatric Cardiology, Paediatric Heart Centre, Department of Surgery, University Children’s Hospital, University of Zurich, Switzerland
* Contributed equally as first/last authors
INTRODUCTION: Congenital heart disease (CHD) is the most frequent birth defect. As survival has significantly improved, attention has turned to neurodevelopmental outcomes of children undergoing heart surgery in early infancy. Since multiple risk factors contribute to neurodevelopmental alterations, a nationwide registry collecting data on medical characteristics, interventions, clinical course and neurodevelopment until school-age is needed to improve the quality of management, identify risk- and protective factors affecting neurodevelopment, and facilitate multicentre trials.
METHODS AND ANALYSIS: The Swiss Outcome Registry for CHIldren with severe congenital heart Disease (ORCHID) is a nationwide, prospective, population-based patient registry developed (1) to collect baseline characteristics and clinical data of CHD patients operated with bypass-surgery or hybrid procedures in the first 6 weeks of life in Switzerland, (2) to monitor long-term neurodevelopment, and (3) to relate clinical characteristics and neurodevelopment to identify risk and protective factors in these children. This registry started data collection relating to pregnancy, birth, preoperative course, catheter-based and surgical treatment, postoperative course and reinterventions in 2019. The primary outcome includes standardised neurodevelopmental assessments at 9 to 12 months, 18 to 24 months and 5.5 to 6 years. We expect to include 80 to 100 children per year. Correlation and regression analyses will be used to investigate risk- and protective factors influencing neurodevelopment.
ETHICS AND DISSEMINATION OF RESULTS: Swiss ORCHID received support by the Accentus Charitable Foundation, the Anna Mueller Grocholoski Stiftung, the Swiss Society of Paediatric Cardiology, the Verein Kinderherzforschung, and the Corelina – Stiftung für das Kinderherz, and was approved by the cantonal ethics committees. Findings will be presented at national and international scientific meetings, and published in peer-reviewed journals. Results will also be shared with patient organizations, primary health care providers, and public health stakeholders to ensure a widespread dissemination of the results.
Congenital heart disease (CHD) is the most frequent birth defect, affecting almost 1% of live births . One in four will have critical CHD and need surgery in the first year of life . Improvement in surgical techniques, catheter-based interventions and perioperative intensive care have made it possible to perform corrective and/or palliative surgery for most severe CHD in the first weeks of life with a gradual drop in perioperative mortality [3–5]. Meanwhile, more than 95% of children born with CHD will survive into adulthood with an at least acceptable quality of life . Therefore, there is nowadays more focus on follow-up, especially to the neurological development of these children [7–9].
Risk factors for brain anomalies and neurodevelopmental impairment in children with severe CHD
Studies have shown that there is a high prevalence of neurodevelopmental impairment in numerous domains but the severity of these problems are low [5, 10]. Up to 50% of children born with severe CHD may show some type of deficit persisting until adolescence and adulthood, including intellectual, behavioural, motor and higher-order cognitive difficulties (executive functions, memory, learning disabilities) [7, 9]. Children requiring cardiac surgery in the neonatal period or as young infants have a higher incidence of neurodevelopmental impairment than children operated on later in childhood [3, 11, 12]. Causes of neurodevelopmental disabilities in children with CHD are multifactorial, involving pathophysiological and medical factors related to the altered fetal brain development, the perinatal adaption, the perioperative course, as well as genetic , or environmental factors such as low socioeconomic status of the family [3, 13]. Structural brain anomalies may occur in children with CHD owing to a genetic comorbidity. In addition, cerebral blood flow, oxygen delivery or both may be altered due to fetal haemodynamic changes related to the CHD, affecting brain growth, connectivity  and central nervous system development in utero [15–18]. In the case of severe CHD, impaired brain development may result in a small brain volume and acquired brain injuries are similar to those seen in preterm neonates [4, 19, 20], most often in the form of white matter injury or cerebral stroke that may be identified after birth pre- or postoperatively, and has shown to be associated with impaired neurodevelopmental outcome . Early diagnosis of CHD (preferably prenatal) allowing an optimised management of the delivery and the perinatal period, is therefore of great importance to avoid prolonged systemic hypoxaemia or cerebral hypoperfusion after birth [3, 21]. Preoperative risk factors for neonatal brain injury include male sex, intravenous prostaglandin infusion, intubation and mechanical ventilation, sedation , hypoxaemia and invasive procedures such as balloon atrial septostomy [3, 23]. Intraoperative risk factors are multiple, including duration of cardiac surgery, cardiopulmonary bypass , aortic clamping and deep hypothermic cardiac arrest, depth of body and brain cooling temperature, time of rewarming, reperfusion injury and inflammation, glycaemic control, pH and haematocrit management, and have all been described to play a role in neurodevelopmental outcome [3, 15, 17]. Similarly, perioperative management of low cardiac output  and thus oxygen delivery, as well as sedation, the risk of paradoxical embolism in presence of right to left shunt, infection, sepsis , hyper- or hypoglycaemia, changes in cerebral blood flow due to acute changes in ventilation can all have a prominent impact on the developing brain . The above-mentioned factors are closely related, and most likely lead to a longer duration of hospital stay, which is the strongest surrogate marker for adverse neurodevelopmental outcome .
There is not only a high socioeconomic burden on the healthcare system of children with CHD, but also a high individual burden to patients and families. Thus, developing multicentre and/or nationwide registers is crucial. To date, many registries have focused on assessing cardiac diagnoses and treatments: examples from the US, Canada, Germany, and Scandinavian countries clearly prove the value of a nationwide, or multicentric data collection to monitor and improve quality of care in patients with CHD [29–35]. However, only few publications report on registries developed to assess long-term neurodevelopmental outcomes and to identify risk-factors for adverse consequences.
Recognising the importance of assessing neurodevelopmental outcome in this population, the American Heart Association issued a scientific statement in 2012, endorsed by the American Academy of Pediatrics, that proposes a framework for assessing neurodevelopmental outcomes . In addition, specific guidelines for the neurodevelopmental evaluation of children with severe CHD from birth to 5 years of age have recently been published . Nevertheless, a systematic nationwide paediatric patient registry for CHD patients in Switzerland, although clearly needed, was lacking until 2019.
Neurodevelopmental follow-up programmes for high-risk neonates in Switzerland
Center-based neurodevelopmental follow-up programmes and registries have been recommended for children with CHD [4, 7, 36]. Neurodevelopmental follow-up programmes allow the early detection of neurodevelopmental delay and the initiation of early interventions for improving outcomes . Neurodevelopmental follow-up includes age-adjusted and standardised tests performed at defined ages during child development. In Switzerland, specific neurodevelopmental follow-up programmes for high-risk newborns (i.e., premature born and neonates with hypoxic-ischaemic encephalopathy) are conducted by the Swiss Neonatal Network and Follow-Up Group (SwissNeoNet). Sixteen follow-up centres across the country perform assessments at 6 to 12 months, 18 to 24 months and 5.5 to 6 years, and enter data in a centralised registry database. SwissNeoNet, inaugurated in 1995, serves as the national medical quality register of the Swiss level III and level IIB neonatal units, and as a collaborative research platform  (https://www.neonet.ch/swissneonet). It was therefore an ideal platform, which could be easily adapted for another high-risk population (i.e., CHD neonates). Neurodevelopmental follow-up of children with CHD requiring open-heart surgery has been introduced stepwise since the year of 2000 in only a few of the above-mentioned centres, which collected data locally. ORCHID allows standardised neurodevelopmental follow-up and focusses on the most complex CHDs and neonatal heart surgery.
Paediatric cardiac centres in Switzerland, creation of a nationwide registry
Around 800 neonates are born annually with CHD in Switzerland. Approximately 80 to 120 are operated on in the first 6 weeks of life. Cardiopulmonary bypass surgery is performed in four paediatric heart centres (Zurich, Bern, Lausanne and Geneva). Until 2019, no nationwide centralised data collection was in place, and neurodevelopmental outcome data were only collected locally by each follow-up centre.
In 2013, the process of establishing a nationwide patient registry was initiated by paediatric cardiologists and developmental paediatricians from the four paediatric heart centres in Switzerland. This core group decided that there was a need for national data collection of neurodevelopmental outcome in children operated on in early life, similar to the follow-up programmes for neonates born preterm or with asphyxia. The network was therefore extended to include a multidisciplinary group of paediatric cardiologists, paediatric intensive care physicians, neonatologists, paediatric cardiac surgeons, paediatric neurologists and developmental paediatricians from the four paediatric heart centres and the follow-up centres, and the existing SwissNeoNet platform was extended and adapted accordingly. In 2018, the Swiss neurodevelopmental Outcome Registry of CHIldren with severe congenital heart Disease (ORCHID) was founded as a collaborative, clinical and scientific research platform.
Aims and hypotheses of the registry
Swiss ORCHID serves as a nationwide, population-based, prospective registry of neurodevelopmental outcome of CHD patients with severe types of CHD, and has the following aims and hypotheses:
- To monitor on a population basis, clinical characteristics of patients with a severe type of CHD operated on in Switzerland within the first 6 weeks of life. Hypotheses: the epidemiological and clinical characteristics will be comparable within the four paediatric heart centres all over Switzerland; centre-specific differences in treatment strategies may potentially affect long-term outcome.
- To monitor the neurodevelopment of this population at 6 to 12 months, 18 to 24 months and 5.5 to 6 years of age. Hypothesis: neurodevelopmental outcome may be more closely related to the severity of the treated type of CHD (and the associated invasiveness of treatments) than to the potential variety of management strategies across centres.
- To identify risk and protective factors for mid-to-long-term neurodevelopment. Hypothesis: due to the large number of patients to be included in Swiss ORCHID and the longitudinal design of the study, data will enable determination of factors predictive of long-term outcome.
Swiss ORCHID enables quality control and improvement, management monitoring, and permits the comparison of cohorts between centres (e.g., if new intervention strategies are implemented). It also constitutes a framework that facilitates patient recruitment for pharmacological and non-pharmacological intervention trials and other prospective collaborative multicentre studies.
Methods and data analysis
Swiss ORCHID (CRC-Trial code: ORCHID) is a prospective multicentre observational data collection (registry) for all children with severe CHD in Switzerland who require a cardiac intervention within the first 6 weeks of life. The registry includes clinical, surgical and neurodevelopmental variables, and has been presented to the cantonal ethics committees (Req-2019-00089). The registry is operated by the Swiss ORCHID group, which consists of a scientific board (representatives of paediatric cardiology, paediatric intensive care and developmental paediatrics from the associated cardiac centres), the follow-up-centres and associated members from all participating centres (fig. 1).
Inclusion criteria, recruitment and number of participants
All neonates (including preterm born children) with severe CHD requiring an intervention within the first 6 weeks of life (cardiac surgery with cardiopulmonary bypass, hybrid procedure or surgery in preparation for later univentricular palliation surgery with cardiopulmonary bypass) at one of the cardiac centres in Switzerland are included in the Swiss ORCHID registry (table 1). Types of surgery included definitive neonatal repair, staged repair or staged palliation leading toward the Fontan procedure. Exclusion criteria are neonates having cardiac surgery or catheter intervention not meeting inclusion criteria (i.e., patent ductus arteriosus, coarctation of the aorta) due to low burden on neurodevelopmental outcome [7, 39] (table 1).
|Cardiac ventricle||Biventricular CHD (staged or definite repair)|
|Primary cardiac diagnosis||Class I: two ventricles without arch obstruction|
|Class II: two ventricles with arch obstruction|
|CHD||D-Transposition of the great arteries (simple/complex)|
|Aortic arch hypoplasia / complex coarctation of the aorta/ interrupted aortic arch|
|Truncus arteriosus communis|
|Total anomalous pulmonary vein return|
|Severe (neonatal) Ebstein anomaly|
|Pulmonary atresia ventricular septum defect (major aorto-to-pulmonary collateral artery )|
|Severe aortic stenosis|
|Others (ALCAPA and other coronary anomalies, aorto-pulmonary window, severe vascular rings and slings)|
|Procedure (examples)||Arterial switch|
|Aortic arch surgery|
|Primary repair or right ventricular to pulmonary artery Sano shunt|
|Total anomalous pulmonary venous return repair|
|Repair or shunt procedure|
|Shunt procedure (unifocalisation, …)|
|Aortic valve repair / Ross|
|Cardiac ventricle||Univentricular CHD (staged procedure)|
|Primary cardiac diagnosis||Class III: single ventricle without arch obstruction||pulmonary duct-dependent perfusion / pulmonary overflow / systemic duct-dependent perfusion|
|Class IV: single ventricle with arch obstruction|
|CHD||Right heart hypoplasia: tricuspid atresia with pulmonary stenosis / pulmonary atresia +ventricular septum defect/ pulmonary atresia+interventricular septum / double inlet left ventricle +transposition of great arteries / others/ tricuspid atresia without pulmonary stenosis / others|
|Left heart hypoplasia: hypoplastic left heart syndrome/complex / Shone complex / dysbalanced atrioventricular septal defect + aortic arch hypoplasia / borderline left ventricle / others|
|Procedure (examples)||Shunt procedure or ductstenting or RVOT opening|
|Pulmonary artery banding, central or bilateral|
|Norwood stage I or Hybrid (patent ductusarteriosus stent / bilateral pulmonary artery banding)|
|Damus-Kaye-Stansel procedure + aortic arch enlargement|
Furthermore, children have to be born and living in Switzerland. To ensure that only children who meet the inclusion criteria are included, registration of participants is restricted to the paediatric heart centres. As no other centres take care of this paediatric population of patients with severe CHD in Switzerland, the Swiss ORCHID registry is designed to be fully population based. We aimed to include 80–100 patients per year but our preliminary data since 2019 shows that we will be including between 50–60 patients per year. For registration and full data entry into the Swiss ORCHID registry, signed informed consent of the parents is necessary. If consent cannot be obtained, or a child dies before the intervention, only a minimal data set is entered into the database.
Data collection and data management
Swiss ORCHID complies with all regulatory standards of good clinical practice. Technically, the Swiss ORCHID database is set up as an extension to the SwissNeoNet and follow-up database (www.swissneonet.ch). The SwissNeoNet web application fulfils information technology security standards with respect to confidentiality, accountability, data integrity and availability. Confidentiality is achieved by restricted access (qualified password protection, centre- and person-specific user rights, encrypted transactions using Transport Layer Security), accountability by access logs, data integrity by recording when a dataset was first setup and each time that it was changed (date, user, field changed, content changed) and availability by performing continuous backups, updating and renewing the infrastructure cyclically, as well as by possessing a disaster recovery and business continuity process plan. The SwissNeoNet data collection is monitored for population coverage, dataset completeness, plausibility and reliability. Data are centrally stored on a secure server in Switzerland.
Patient recruitment, data collection and use of data of the Swiss ORCHID registry is displayed in figure 2. Each of the four paediatric heart centres is accountable for registering new patients, entering baseline data and subsequently referring the patient and family to the follow-up centre closest to their home. If families give consent to enter their child`s data into the registry, data entry includes date of birth, and a patient identifier in order to be able to find individual datasets and to add additional data on clinical course and neurodevelopmental outcome. For all other patients, despite those who definitely refused consent, an anonymised minimal data set is entered. Centralised monitoring is provided by a data management team. All data exports from the registry are coded and secured.
The start of data collection was 01 January 2019. Preliminary data are summarised at the end of the manuscript.
Anonymised data can be made available to ORCHID investigators for research projects when legal requirements are met. These include approval of the study protocol by one cantonal ethics review board, which is then also valid for (national) multicentre use. Currently, data usage by regional, national or international research projects is not planned. Researchers interested in collaborative work can contact the authors to discuss planned projects or analyse existing data. The decision on collaboration is made by the scientific board of the Swiss ORCHID.
Two projects have recently been submitted to the scientific board of the Swiss ORCHID and are currently being evaluated: (1) neurodvelopmental outcome in patients with preoperative levosimendan infusion and (2) the impact of necrotising enterocolitis on neurodevelopmental outcome.
The type of data collected at different time points for different groups of patients is displayed in table 2; detailed information on all collected variables is provided in tables 3 and 4. If a child dies before the first intervention, only an anonymous, minimal dataset is entered into the database, consisting of the primary cardiac diagnosis and cardiac diagnosis group, sex, year of birth, birth location and cause of death. For all registered children whose data are fully entered, different procedures are followed depending on the type (univentricular or biventricular) of CHD. Data are entered after the first surgery for all children, after any other consecutive surgeries (depending on the type of CHD in children with biventricular CHD), and after stage 2 and stage 3 surgery for patients with univentricular CHD (tables 2 and 3). Follow-up data are entered for all children following routine visits at 9–12 months, 8–24 months, and 5.5–6 years of age (tables 2 and 4).
|Data variables||Timepoint patient group|
|Registered uni- or biventricular CHD patients||Death prior to consent|
|Patient information, baseline medical data, pregnancy, presurgical||x|
|Data after stage 1, or first surgery|
|Surgery/intervention, postoperative, discharge at end of stage||x|
|Data after any other biventricular surgery or after stage 2 and 3 (univentricular CHD)|
|General data, presurgical, surgery, postoperative, discharge||x|
|Neurodevelopmental assessment at 9–12 months|
|Socioeconomic status, medical history, somatic growth parameters, physical examination||x|
|BSID-III cognitive, language and motor scales||x|
|Neurodevelopmental assessment at 18–24 months|
|Socioeconomic status, medical history, somatic growth parameters, physical exam||x|
|BSID-III cognitive, language and motor scales||x|
|Neurodevelopmental assessment at 5.5–6 years|
|Socioeconomic status, medical history, somatic growth parameters, physical exam||x|
|K-ABC II general intelligence composite score||x|
|ZNA-2 motor performance||x|
|Data variables||TimepointPatient group|
|Registered uni- or biventricular CHD patients||Death prior to consent|
|Minimal dataset||Cardiac centre entering the data, place of birth, year of birth, sex, cardiac diagnosis, type of CHD, year of death*, cause of death*||X||X|
|Baseline characteristics||Patient information||Swiss ORCHID-ID-Nr., cardiac centre entering the data1, informed consent, place of birth, date/year1 of birth, sex1, gestational age||X|
|Baseline medical data||Cardiac diagnosis1, type of CHD1, weight, length, head circumference, year of death1,*, cause of death1,*||X|
|Presurgical||Delivery mode, birth adaptation (Apgar score, umbilical artery cord pH, lactate), feeding, intubation, respiratory support, cardiac medication, preductal saturation, haematocrit, creatinine, lactate, need for resuscitation, seizures, cerebral MRI or cranial ultrasound (classification of results if performed)||X|
|Data after stage 1 or first surgery||Surgery/intervention||Age at time of catheter, age at surgery with cardiopulmonary bypass, type of interventional cardiac catheter, cardiac surgery type, RACHS score, CICU discharge day, cardiopulmonary bypass time, aortic cross clamp time, circulatory arrest time, antegrade cerebral perfusion, lowest temperature, ultrafiltration||X|
|Postoperative||Lactate peak value within 24 first hours, need for repeat surgery with or without cardiopulmonary bypass, cardiac catheter, resuscitation, ECMO and type of ECMO, drugs and duration, arrhythmias or block and treatment, duration of intubation, noninvasive ventilation, nitric oxide, oxygen, highest postoperative creatinine value, renal replacement therapy, complications after surgery (infection, diaphragmatic paralysis, chylothorax…), cerebral MRI or cranial ultrasound (date and classification of results if performed), death within 30 days postoperative||X|
|Discharge at end of stage||Day of discharge, overall number of days in CICU, destination at discharge, medication at discharge, growth parameters, transcutaneous saturation, tube feeding||X|
|Data after any other biventricular surgery, or after stage 2 and 3 (univentricular CHD)||General data||Age, day of admission or surgery if still hospitalised, growth parameters||X|
|Presurgical||Repeat surgery between stage 1 discharge and stage 2 with or without cardiopulmonary bypass, cardiac catheter intervention between stage 1 and 2, preoperative intubation and duration, other respiratory support and its duration, preductal saturation, haematocrit, NYHA classification, need for resuscitation, medications, preoperative feeding, seizures||X|
|Surgery||Age at surgery, cardiac surgery with cardiopulmonary bypass, type of surgery, cardiac surgery shunt procedure, RACHS, CICU discharge day, cardiopulmonary bypass, aortic cross clamp and circulatory arrest durations, antegrade cerebral perfusion, lowest temperature, ultrafiltration||X|
|Postoperative||Lactate peak value within first 24 hours, repeat surgery with or without cardiopulmonary bypass, cardiac catheter intervention, need for resuscitation and duration, ECMO and type of ECMO, medications and duration, arrhythmias or block and treatment, duration of intubation, noninvasive ventilation, nitric oxide, oxygen, highest postoperative creatinine value, renal replacement therapy, complications after surgery (infection, diaphragmatic paralysis, chylothorax…), death within 30 days postoperative||X|
|Discharge||Day of discharge, overall number of days in CICU, destination at discharge, medication at discharge, growth parameters, transcutaneous saturation, tube feeding||X|
|Data category||Data variables||Age at assessment|
|9 to 12 and 18 to 24 months||5.5 to 6 years|
|Socioeconomic status||Parents’ education and current occupation||X||X|
|Medical history||Cardiac medication, hospitalisation during the first year, interventions during the first year (repeat cardiac surgery, catheter intervention or other interventions), tube feeding||X||X|
|Current therapy (early intervention, physiotherapy, occupational, psychology, other…)|
|Somatic growth parameters, physical exam||Height, weight, head circumference||X||X|
|Cerebral palsy and GMCFS, non-cerebral-palsy neuromotor abnormalities|
|Sensory assessment (visual impairment, hearing impairments)|
|Other neurodevelopmental abnormalities (fetal alcohol syndrome, genetic disorder, congenital infection, attention-deficit hyperactivity disorder, autistic spectrum disorder, speech impairment, epilepsy, …)|
|Assessment tools||BSID-III cognitive, language, and motor standard scale||X|
|K-ABC II general intelligence composite score / ZNA-2 motor performance||X|
Primary outcome measures: neurodevelopmental follow-up
Routine neurodevelopmental follow-up is at three different ages: 9–12 months, 18–24 months and 5.5–6 years. Assessments take place at the 16 follow-up centres all over Switzerland, which are also responsible for follow-up and data entry for other at-risk groups within the SwissNeoNet  framework. Up to an age of 42 months (3½ years), neurodevelopmental assessments are performed using the Bayley Scales for Infant and Toddler Development, 3rd Edition (BSID-III) , which comprises cognitive, language and motor subscores. In addition, neurological examination allows detection of cerebral palsy, which is graded according to the Gross Motor Function Classification System (GMCFS) . At 5.5–6 years of age, the Kaufman Assessment Battery for Children, 2nd Edition (KABC-II) is used for cognitive evaluation . This test includes five subscales that explore several aspects of intelligence including simultaneous and sequential fluid reasoning, visual processing, short term memory, planning, learning, and knowledge. In addition, a neuro-orthopaedic examination and the Zurich Neuromotor Assessment, 2nd Edition (ZNA-2)  are performed. The latter assesses motor functions during this early school age visit, evaluating quality of movement, motor coordination, balance and adaptive fine and gross motor tasks. For timepoints and instruments used, see tables 2 and 4.
Secondary outcome measures
Secondary outcome measures will be defined in the context of future study protocols, based on the Swiss ORCHID registry. They could include functional cardiac variables, as well as assessments of health-related quality of life, behaviour, executive functions, attention, parenting style, parental satisfaction, parental needs, or others.
Endorsement or collaboration
ORCHID members are key stakeholders in the fields of Swiss paediatric cardiology, cardiac surgery, paediatric intensive care, paediatric anesthesia, and developmental paediatrics. ORCHID is cooperating with the “Verein Kinderherzforschung” (VKHFS) and is in close contact with patient and parent associations. The Swiss ORCHID will provide a large amount of prospectively collected data on the clinical characteristics of, and surgical strategies used to treat, CHD patients in Switzerland and their relationship with the neurodevelopment outcome of this vulnerable population. By gathering a large number of patients, the registry will enable an increase in the sample size for multicentre studies and allow more robust statistical analyses.
Swiss ORCHID is endorsed by the Swiss Society of Paediatric Cardiology (SSCP), and the Swiss Society of Developmental Pediatrics (SGEP). ORCHID representatives are also members of scientific societies (e.g., Swiss Heart Foundation, European Society of Paediatric Research, Cardiac Neurodevelopmental Outcome Collaborative, Newborn Brain Society, Swiss Society of Intensive Care Medicine [SSIGM], European Society of Paediatric and Neonatal Intensive Care [ESPNIC]). All of the above-mentioned channels are important to disseminate our findings.
Patient and public involvement
Patient and parent associations were not directly involved in the ORCHID registry conception. However, patient representatives will be invited as consultants in the future in order to integrate their perspectives into development of future research questions, study design, choice of outcome measures, as well as to facilitate recruitment.
After a patient’s data has been checked by our database manager for completeness, plausibility and consistency, we randomly perform control checks to detect systematic mistakes during data entry. In addition, selected data points are cross-checked for plausibility with previously entered data. Descriptive statistics will include means with standard deviations (SD), and interquartile ranges (IQRs) for continuous variables, and number and percentage for categorical variables. T-tests will be used for continuous variables and χ2 tests for categorical variables. Associations between potential risk factors and neurodevelopmental outcome will be investigated using linear regression analyses. For these models, potential confounders will be included in the models. For these and further statistics, appropriate data analyses will be selected based on the research question and performed using dedicated programs (STATA, R, SPSS). All analyses will be conducted with an alpha level of 0.05. Bonferroni or false discovery rate correction will be applied if needed. In the case that the data do not meet the assumptions of linearity and normality, nonparametric tests will be performed.
Ethics and dissemination of results
The Swiss ORCHID registry has been reviewed by the cantonal ethics committees in charge of each of the paediatric heart centres (Req-2019-00089). Oral and written information about the registry is given to the patient’s parents or legal guardians in either the pre- or postoperative period. If consent cannot be obtained prior to discharge from hospital, families can be asked to give their consent at the first follow-up visit. Parents or legal guardians sign a written consent form to make anonymised registry data of their child accessible for further scientific use. To enrol patients for future studies, each particular research project based on the registry has to undergo another, specific approval procedure by the cantonal ethics committees. The registry fosters national collaboration and standardisation of practices, and will form the basis of research projects aiming at improving management and monitoring outcome after new intervention strategies. Annual reports go to all participating centres and collaborators for quality control purposes, as well as to the funders, parent organisations, healthcare stakeholders and the endorsing medical associations. Findings will also be presented at national and international scientific meetings, and published in peer-reviewed journals to ensure a widespread dissemination of the results.
Between 2019 and 2021, 161 patients met the inclusion criteria. Of these, we received informed consent of 138 families and could record complete data sets. Reasons for patients not fulfilling the inclusion criteria were no consent given (n = 3), death before available consent (n = 12), or incomplete dataset (n = 8).
The most common type of CHD was transposition of the great arteries, (n = 50, 31.1%) followed by single ventricle CHD (n = 32, 19.9%), the latter requiring a 3-stage surgical management (table 5.)
|Cardiac diagnosis||Number of patients||Percentage|
|Hypoplastic left heart syndrome||20||12.4%|
|Single ventricle, other||12||7.5%|
|Transposition of great arteries||50||31.1%|
|Aortic coarctation / hypoplastic aortic or interrupted aortic arch||15||9.3%|
|Common arterial truncus||10||6.2%|
|Pulmonary atresia + ventricular septum defect / tetralogy of Fallot||6||3.7%|
|Pulmonary atresia + interventricular septum||6||3.7%|
|Total anomalous pulmonary venous return / partial anomalous pulmonary venous return||11||6.8%|
|Unknown (incomplete data so far)||4||2.5%|
The neurodevelopmental Outcome Registry for CHIldren with severe congenital heart Disease (ORCHID) is based on an interdisciplinary network of collaborating paediatric cardiologists, developmental paediatricians, paediatric intensive care and anaesthesiologists, neonatologists, and paediatric cardiac surgeons, to ensure a wide range of viewpoints and contributions to new research projects that will use registry data. Standardised neurodevelopmental outcome assessment after early invasive surgical or catheter-interventional treatment of neonates affected by a severe form of CHD in a nationwide registry facilitates quality improvement, allows comparison of strategies of care, and lowers the threshold for multicentre trials. Utilising the structure and established protocols of a pre-existing registry (SwissNeoNet) along with discussion with the involved centres and experts as a basis for ORCHID proved to be cost effective and time saving. The data collection will enable a better understanding of clinical risk factors for neurodevelopmental impairments, although direct comparisons of participating centres will remain limited due to the variety of differences in treatment procedures between paediatric heart centres.
The Swiss ORCHID group including follow-up is composed of the following members: Lausanne: Nicole Sekarski, Julia Natterer, Christelle L’Ebraly, Juliane Schneider, René Prêtre; Geneva: Maya Sabrina Bouhabib, Angelo Polito, Cristina Borradori Tolsa, Tornike Sologahsvili; Zürich: Walter Knirsch, Janet Kelly, Verena Rathke, Michael von Rhein, Ruth Etter, Bea Latal, Hitendu Dave, Robert Cesnjevar; Berne: Damian Hutter, Marc Raphael Pfluger, Martin Glöckler, Sebastian Grunt, Katharina Fuhrer Kradolfer, Alexander Kadner; Basel: Mark Brotzmann; Aarau: Hannah Kümin: Luzern: Florian Bauder; Chur: Christa Killer; St. Gallen: Ursula Speckle; Winterthur: Ulla Jochumsen; Bellinzona: Barbara Goeggel-Simonetti; Solothurn: Letizia von Laer; Münsterlingen: Seraina Calonder-Faas; Biel: Lena-Marie Gerecke; Fribourg: Marie-Pascale Metrailler. Technical responsibility for the database and hosting via Swiss Neonet Platform: Mark Adams.
Author contributions: JN and JS wrote the first draft. BL and WK conceived and initiated the registry. NS, CBT, JB, MB, KF, MG, DH, JK, CL, MP, AP, MvR, and WK are steering committee members of the Swiss ORCHID, who designed and developed the registry, and gave valuable input to the manuscript. MvR, WK, and NS critically revised the manuscript. VR and MA added many details and proof-read the text.
The Swiss ORCHID has been supported by different grants of the Accentus Charitable Foundation, the Anna Mueller Grocholoski Stiftung, the Swiss Society of Paediatric Cardiology and the Corelina- Stiftung für das Kinderherz (grant number: Forschungsprojekt Swiss ORCHID Nr. 20287). WK is supported by the Swiss National Science Foundation with a Grant Protected Research Time for Clinicians as part of his SNSF project (320030_184932 / 2).
Potential competing interests
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflict of interest was disclosed.
Prof. Nicole Sekarski, MD
University Hospital Lausanne
Rue du Bugnon 46
2. Lytzen R, Vejlstrup N, Bjerre J, Petersen OB, Leenskjold S, Dodd JK Live-Born Major Congenital Heart Disease in Denmark: Incidence, Detection Rate, and Termination of Pregnancy Rate From 1996 to 2013. JAMA Cardiol. 2018 Sep;3(9):829–37. http://dx.doi.org/10.1001/jamacardio.2018.2009 PubMed 2380-6591
3. Wernovsky G. Current insights regarding neurological and developmental abnormalities in children and young adults with complex congenital cardiac disease. Cardiol Young. 2006 Feb;16(S1 Suppl 1):92–104. http://dx.doi.org/10.1017/S1047951105002398 PubMed 1047-9511
4. Brosig C, Butcher J, Butler S, Ilardi DL, Sananes R, Sanz JH Monitoring developmental risk and promoting success for children with congenital heart disease: recommendations for cardiac neurodevelopmental follow-up programs. Clin Pract Pediatr Psychol. 2014;2(2):153–65. http://dx.doi.org/10.1037/cpp0000058 2169-4834
7. Marino BS, Lipkin PH, Newburger JW, Peacock G, Gerdes M, Gaynor JW, American Heart Association Congenital Heart Defects Committee, Council on Cardiovascular Disease in the Young, Council on Cardiovascular Nursing, and Stroke Council. Neurodevelopmental outcomes in children with congenital heart disease: evaluation and management: a scientific statement from the American Heart Association. Circulation. 2012 Aug;126(9):1143–72. http://dx.doi.org/10.1161/CIR.0b013e318265ee8a PubMed 1524-4539
8. Bolduc ME, Rennick JE, Gagnon I, Majnemer A, Brossard-Racine M. Canadian Developmental Follow-up Practices in Children With Congenital Heart Defects: A National Environmental Scan. CJC Pediatric and Congenital Heart Disease. 2022;1(1):3–10. http://dx.doi.org/10.1016/j.cjcpc.2021.11.002 2772-8129
10. Liamlahi R, Latal B. Neurodevelopmental outcome of children with congenital heart disease. Handb Clin Neurol. 2019;162:329–45. http://dx.doi.org/10.1016/B978-0-444-64029-1.00016-3 PubMed 0072-9752
11. Wernovsky G. Outcomes regarding the central nervous system in children with complex congenital cardiac malformations. Cardiol Young. 2005 Feb;15(S1 Suppl 1):132–3. http://dx.doi.org/10.1017/S1047951105001162 PubMed 1047-9511
12. Feldmann M, Bataillard C, Ehrler M, Ullrich C, Knirsch W, Gosteli-Peter MA Cognitive and Executive Function in Congenital Heart Disease: A Meta-analysis. Pediatrics. 2021 Oct;148(4):e2021050875. http://dx.doi.org/10.1542/peds.2021-050875 PubMed 1098-4275
13. Naef N, Liamlahi R, Beck I, Bernet V, Dave H, Knirsch W Neurodevelopmental Profiles of Children with Congenital Heart Disease at School Age. J Pediatr. 2017 Sep;188:75–81. http://dx.doi.org/10.1016/j.jpeds.2017.05.073 PubMed 1097-6833
14. Feldmann M, Guo T, Miller SP, Knirsch W, Kottke R, Hagmann C Delayed maturation of the structural brain connectome in neonates with congenital heart disease. Brain Commun. 2020 Nov;2(2):fcaa209. http://dx.doi.org/10.1093/braincomms/fcaa209 PubMed 2632-1297
15. Massaro AN, El-Dib M, Glass P, Aly H. Factors associated with adverse neurodevelopmental outcomes in infants with congenital heart disease. Brain Dev. 2008 Aug;30(7):437–46. http://dx.doi.org/10.1016/j.braindev.2007.12.013 PubMed 0387-7604
16. Chock VY, Reddy VM, Bernstein D, Madan A. Neurologic events in neonates treated surgically for congenital heart disease. J Perinatol. 2006 Apr;26(4):237–42. http://dx.doi.org/10.1038/sj.jp.7211459 PubMed 0743-8346
17. Howell HB, Zaccario M, Kazmi SH, Desai P, Sklamberg FE, Mally P. Neurodevelopmental outcomes of children with congenital heart disease: A review. Curr Probl Pediatr Adolesc Health Care. 2019 Oct;49(10):100685. http://dx.doi.org/10.1016/j.cppeds.2019.100685 PubMed 1538-3199
18. Sun L, van Amerom JF, Marini D, Portnoy S, Lee FT, Saini BS MRI characterization of hemodynamic patterns of human fetuses with cyanotic congenital heart disease. Ultrasound Obstet Gynecol. 2021 Dec;58(6):824–36. http://dx.doi.org/10.1002/uog.23707 PubMed 1469-0705
19. Peyvandi S, Latal B, Miller SP, McQuillen PS. The neonatal brain in critical congenital heart disease: insights and future directions. Neuroimage. 2019 Jan;185:776–82. http://dx.doi.org/10.1016/j.neuroimage.2018.05.045 PubMed 1095-9572
20. Stegeman R, Feldmann M, Claessens NH, Jansen NJ, Breur JM, de Vries LS, European Association Brain in Congenital Heart Disease Consortium. A Uniform Description of Perioperative Brain MRI Findings in Infants with Severe Congenital Heart Disease: results of a European Collaboration. AJNR Am J Neuroradiol. 2021 Nov;42(11):2034–9. http://dx.doi.org/10.3174/ajnr.A7328 PubMed 1936-959X
21. Algra SO, Haas F, Poskitt KJ, Groenendaal F, Schouten AN, Jansen NJ Minimizing the risk of preoperative brain injury in neonates with aortic arch obstruction. J Pediatr. 2014 Dec;165(6):1116–1122.e3. http://dx.doi.org/10.1016/j.jpeds.2014.08.066 PubMed 1097-6833
22. Lynch JM, Buckley EM, Schwab PJ, McCarthy AL, Winters ME, Busch DR Time to surgery and preoperative cerebral hemodynamics predict postoperative white matter injury in neonates with hypoplastic left heart syndrome. J Thorac Cardiovasc Surg. 2014 Nov;148(5):2181–8. http://dx.doi.org/10.1016/j.jtcvs.2014.05.081 PubMed 1097-685X
23. Petit CJ, Rome JJ, Wernovsky G, Mason SE, Shera DM, Nicolson SC Preoperative brain injury in transposition of the great arteries is associated with oxygenation and time to surgery, not balloon atrial septostomy. Circulation. 2009 Feb;119(5):709–16. http://dx.doi.org/10.1161/CIRCULATIONAHA.107.760819 PubMed 1524-4539
24. Dimitropoulos A, McQuillen PS, Sethi V, Moosa A, Chau V, Xu D Brain injury and development in newborns with critical congenital heart disease. Neurology. 2013 Jul;81(3):241–8. http://dx.doi.org/10.1212/WNL.0b013e31829bfdcf PubMed 1526-632X
25. Claessens NH, Chau V, de Vries LS, Jansen NJ, Au-Young SH, Stegeman R Brain Injury in Infants with Critical Congenital Heart Disease: Insights from Two Clinical Cohorts with Different Practice Approaches. J Pediatr. 2019 Dec;215:75–82.e2. http://dx.doi.org/10.1016/j.jpeds.2019.07.017 PubMed 1097-6833
26. Atallah J, Garcia Guerra G, Joffe AR, Bond GY, Islam S, Ricci MF, Western Canadian Complex Pediatric Therapies Follow‐up Program*. Survival, Neurocognitive, and Functional Outcomes After Completion of Staged Surgical Palliation in a Cohort of Patients With Hypoplastic Left Heart Syndrome. J Am Heart Assoc. 2020 Feb;9(4):e013632. http://dx.doi.org/10.1161/JAHA.119.013632 PubMed 2047-9980
27. Newburger JW, Wypij D, Bellinger DC, du Plessis AJ, Kuban KC, Rappaport LA Length of stay after infant heart surgery is related to cognitive outcome at age 8 years. J Pediatr. 2003 Jul;143(1):67–73. http://dx.doi.org/10.1016/S0022-3476(03)00183-5 PubMed 0022-3476
28. Gaynor JW, Stopp C, Wypij D, Andropoulos DB, Atallah J, Atz AM, International Cardiac Collaborative on Neurodevelopment (ICCON) Investigators. Neurodevelopmental outcomes after cardiac surgery in infancy. Pediatrics. 2015 May;135(5):816–25. http://dx.doi.org/10.1542/peds.2014-3825 PubMed 1098-4275
29. Beckmann A, Dittrich S, Arenz C, Krogmann ON, Horke A, Tengler A German Registry for Cardiac Operations and Interventions in Patients with Congenital Heart Disease: Report 2020-Comprehensive Data from 6 Years of Experience. Thorac Cardiovasc Surg. 2021;69(S 03):e21-e31.
30. Alsaied T, Allen KY, Anderson JB, Anixt JS, Brown DW, Cetta F The Fontan outcomes network: first steps towards building a lifespan registry for individuals with Fontan circulation in the United States. Cardiol Young. 2020 Aug;30(8):1070–5. http://dx.doi.org/10.1017/S1047951120001869 PubMed 1467-1107
31. Marino BS, Sood E, Cassidy AR, Miller TA, Sanz JH, Bellinger D The origins and development of the cardiac neurodevelopment outcome collaborative: creating innovative clinical, quality improvement, and research opportunities. Cardiol Young. 2020 Nov;30(11):1597–602. http://dx.doi.org/10.1017/S1047951120003510 PubMed 1467-1107
32. Bates KE, Yu S, Mangeot C, Shea JA, Brown DW, Uzark K. Identifying best practices in interstage care: using a positive deviance approach within the National Pediatric Cardiology Quality Improvement Collaborative. Cardiol Young. 2019 Mar;29(3):398–407. http://dx.doi.org/10.1017/S1047951118002548 PubMed 1467-1107
33. Svensson B, Idvall E, Nilsson F, Liuba P. Health-related quality of life in children with surgery for CHD: a study from the Swedish National Registry for Congenital Heart Disease. Cardiol Young. 2017 Mar;27(2):333–43. http://dx.doi.org/10.1017/S1047951116000585 PubMed 1467-1107
34. Olsen M, Christensen TD, Pedersen L, Johnsen SP, Hjortdal VE. Late mortality among Danish patients with congenital heart defect. Am J Cardiol. 2010 Nov;106(9):1322–6. http://dx.doi.org/10.1016/j.amjcard.2010.06.062 PubMed 1879-1913
35. Robertson CM, Sauve RS, Joffe AR, Alton GY, Moddemann DM, Blakley PM The registry and follow-up of complex pediatric therapies program of Western Canada: a mechanism for service, audit, and research after life-saving therapies for young children. Cardiol Res Pract. 2011;2011:965740. http://dx.doi.org/10.4061/2011/965740 PubMed 2090-0597
36. Ware J, Butcher JL, Latal B, Sadhwani A, Rollins CK, Brosig Soto CL Neurodevelopmental evaluation strategies for children with congenital heart disease aged birth through 5 years: recommendations from the cardiac neurodevelopmental outcome collaborative. Cardiol Young. 2020 Nov;30(11):1609–22. http://dx.doi.org/10.1017/S1047951120003534 PubMed 1467-1107
37. Fourdain S, Simard MN, Dagenais L, Materassi M, Doussau A, Goulet J Gross Motor Development of Children with Congenital Heart Disease Receiving Early Systematic Surveillance and Individualized Intervention: brief Report. Dev Neurorehabil. 2021 Jan;24(1):56–62. http://dx.doi.org/10.1080/17518423.2020.1711541 PubMed 1751-8431
38. Adams MB, Bucher HU. Un début précoce dans la vie: qu’apporte un registre national? Forum Med Suisse. 2013;13(3):35–7. http://dx.doi.org/10.4414/fms.2013.01397 1661-6146
39. McQuillen PS, Miller SP. Congenital heart disease and brain development. Ann N Y Acad Sci. 2010 Jan;1184(1):68–86. http://dx.doi.org/10.1111/j.1749-6632.2009.05116.x PubMed 1749-6632
40. Adams MB, Bickle Graz M, Grunt S, Weber P, Capone Mori A, Bauder F Follow-up assessment of high-risk newborns in Switzerland. Recommendations of the Swiss Society of Neonatology, the Swiss Society of Developmental Pediatrics and the Swiss Society of Neuropediatrics. Paediatrica. 2014;25(5):6–10.
41. Albers CA, Grieve AJ. Test Review: Bayley, N. (2006). Bayley Scales of Infant and Toddler Development– Third Edition. San Antonio, TX: Harcourt Assessment. 2007;25(2):180-90.
42. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997 Apr;39(4):214–23. http://dx.doi.org/10.1111/j.1469-8749.1997.tb07414.x PubMed 0012-1622
43. Bain SK, Gray R. Test Reviews: Kaufman, A. S., & Kaufman, N. L. (2004). Kaufman Assessment Battery for Children, Second edition. Circle Pines, MN: AGS. 2008;26(1):92-101.
44. Largo RH, Caflisch JA, Hug F, Muggli K, Molnar AA, Molinari L Neuromotor development from 5 to 18 years. Part 1: timed performance. Dev Med Child Neurol. 2001 Jul;43(7):436–43. http://dx.doi.org/10.1017/S0012162201000810 PubMed 0012-1622
Published under the copyright license CC BY-NC-SA: This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.